Aileron Therapeutics Inc (ALRN)
3.79
-0.06
(-1.56%)
USD |
NASDAQ |
May 17, 16:00
3.79
0.00 (0.00%)
After-Hours: 20:00
Aileron Therapeutics SG&A Expense (Quarterly): 5.33M for Dec. 31, 2023
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 5.33M |
| September 30, 2023 | 1.955M |
| June 30, 2023 | 1.893M |
| March 31, 2023 | 2.179M |
| December 31, 2022 | 2.301M |
| September 30, 2022 | 2.243M |
| June 30, 2022 | 2.608M |
| March 31, 2022 | 2.528M |
| December 31, 2021 | 2.255M |
| September 30, 2021 | 2.513M |
| June 30, 2021 | 2.156M |
| March 31, 2021 | 2.673M |
| December 31, 2020 | 2.267M |
| September 30, 2020 | 2.344M |
| June 30, 2020 | 1.912M |
| March 31, 2020 | 2.807M |
| Date | Value |
|---|---|
| December 31, 2019 | 2.639M |
| September 30, 2019 | 3.44M |
| June 30, 2019 | 3.075M |
| March 31, 2019 | 3.139M |
| December 31, 2018 | 3.021M |
| September 30, 2018 | 3.177M |
| June 30, 2018 | 4.339M |
| March 31, 2018 | 2.917M |
| December 31, 2017 | 2.73M |
| September 30, 2017 | 2.601M |
| June 30, 2017 | 1.791M |
| March 31, 2017 | 1.647M |
| December 31, 2016 | 1.356M |
| September 30, 2016 | 1.627M |
| June 30, 2016 | 3.464M |
| March 31, 2016 | 1.446M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
1.893M
Minimum
Jun 2023
5.33M
Maximum
Dec 2023
2.585M
Average
2.344M
Median
Sep 2020
SG&A Expense (Quarterly) Benchmarks
| EyePoint Pharmaceuticals Inc | 14.11M |
| INVO Bioscience Inc | 1.856M |
| Bio-Path Holdings Inc | 0.757M |
| SINTX Technologies Inc | 1.369M |
| NovaBay Pharmaceuticals Inc | 3.346M |